Project: Novel treatment for anti-estrogen therapy resistance: a paradigm shift in breast cancer treatment
| Acronym | ENDORESIST (Reference Number: 114189) |
| Duration | 01/09/2020 - 01/03/2023 |
| Project Topic | ENDORESIST aims at seizing a major market opportunity by developing SCO-101, a new drug that targets anti-estrogen resistance in breast cancer treatment. We will deliver a clinically validated and safe drug, and a companion diagnostic tool, opening the possibility to find a big pharma buyer/partner to capitalize on the SCO-101. ENDORESIST builds around a patient-centric approach, based on biomarker discovery and insights on mechanisms of action. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 13 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | 2cureX A/S | Partner | Denmark |
| 2 | Medical Oncology department of Erasmus Universitair Medisch Centrum Rotterdam | Partner | Netherlands |
| 3 | Scandion Oncology A/S | Coordinator | Denmark |